Results 151 to 160 of about 30,927 (236)

IBRUTINIB FOR RELAPSED / REFRACTORY CLL: AN UPDATE OF THE UK AND IRELAND ANALYSIS OF OUTCOMES IN 315 PATIENTS [PDF]

, 2017
George Follows, U.K. CLL Forum
openalex   +1 more source

Cost impact of Bruton's tyrosine kinase inhibitor selection in Medicare patients with chronic lymphocytic leukemia. [PDF]

J Comp Eff Res
Kittai AS, Patel DA, Shafrin J, Zawadzki N, Shetty VS, Barqawi YK, Rhodes JM.   +6 more
europepmc   +1 more source

IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL [PDF]

, 2017
Paula Cramer, Fatih Demırkan, Graeme Fraser, Alexander Pristupa, Nancy L. Bartlett, M.S. Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, André Goy, Siddhartha Ganguly, Italo Poggesi, Silvia Maria Lavezzi, Giuseppe De Nicolao, Jan de Jong, Martine Neyens, Mariya Salman, Angela Howes, Michelle Mahler   +19 more
openalex   +1 more source

IBRUTINIB IN ASSOCIATION WITH R‐DHAP/OX FOR PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMA: PRELIMINARY RESULTS OF THE BIBLOS PHASE IB LYSA STUDY [PDF]

, 2017
Christophe Bonnet, Thierry Lamy, Christophe Fruchart, Steven Le Gouill, K. Gunzer, Thomas Gastinne, Fabrice Jardin, Lionel Karlin, Roch Houot, Jehan Dupuis, Hervé Tilly, Gilles Salles   +11 more
openalex   +1 more source

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells. [PDF]

Cancer Immunol Immunother
Bopp AR, Lamenza FF, Upadhaya P, Ryan NM, Kazmierowicz N, Jordanides PP, Siddiqui A, Pracha SH, Roth P, Iwenofu OH, Oghumu S.   +10 more
europepmc   +1 more source

Venetoclax Consolidation After Bruton Tyrosine Kinase Inhibitor Treatment for Patients With Chronic Lymphocytic Leukemia. [PDF]

EJHaem
Heyman B, Choi M, Kipps TJ.
europepmc   +1 more source

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib [PDF]

, 2016
Advani, Bohers, Cao, Cao, Cheng, Chng, Christopher J. Patterson, Evans, Farré, Gay, Guang Yang, Gutiérrez, Hallek, Hanke, Hong, Honigberg, Janz, Jennifer R. Brown, Jiaji G. Chen, Jie Chen, Jorge J. Castillo, Jourdan, Juilland, Lam, Leleu, Li Tan, Lian Xu, Messeguer, Musumeci, Nathanael Gray, Ngo, Nicholas Tsakmaklis, O’Boyle, Patricelli, Pecquet, Pene-Dumitrescu, Philip Cohen, Poh, Sahota, Saito, Sanner, Sara J. Buhrlage, Schaeffer, Shuai Liu, Steven P. Treon, Suh, Taguchi, Treon, Treon, Treon, Trott, Varettoni, Wei Zhang, Wilson, Woyach, Xia Liu, Xiaofeng Zhang, Xu, Yang, Yang, Zachary R. Hunter   +60 more
core   +2 more sources

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia

, 2017
Benjamin J. Arthurs, Kathy Wunderle, Maylee Hsu, Suil Kim   +3 more
openalex   +1 more source

AreBTKandPLCG2mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? [PDF]

, 2018
Benjamin L. Lampson, Jennifer R. Brown
openalex   +1 more source

A Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network. [PDF]

Pharmacol Res Perspect
Majrashi A, Gue YX, Shantsila A, Williams S, Smith CT, Lip GYH, Pettitt AR.   +6 more
europepmc   +1 more source